William F.  Feehery net worth and biography

William Feehery Biography and Net Worth

CEO of Certara

Dr. Feehery joined Certara in June, 2019 as CEO.  Dr. Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group.

Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.

Dr. Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University, and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.

What is William F. Feehery's net worth?

The estimated net worth of William F. Feehery is at least $56.12 million as of August 25th, 2021. Dr. Feehery owns 3,138,743 shares of Certara stock worth more than $56,120,725 as of March 29th. This net worth approximation does not reflect any other assets that Dr. Feehery may own. Additionally, Dr. Feehery receives an annual salary of $1,350,000.00 as CEO at Certara. Learn More about William F. Feehery's net worth.

How old is William F. Feehery?

Dr. Feehery is currently 53 years old. There are 4 older executives and no younger executives at Certara. Learn More on William F. Feehery's age.

What is William F. Feehery's salary?

As the CEO of Certara, Inc., Dr. Feehery earns $1,350,000.00 per year. Learn More on William F. Feehery's salary.

How do I contact William F. Feehery?

The corporate mailing address for Dr. Feehery and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on William F. Feehery's contact information.

Has William F. Feehery been buying or selling shares of Certara?

William F. Feehery has not been actively trading shares of Certara within the last three months. Most recently, William F. Feehery sold 90,000 shares of the business's stock in a transaction on Thursday, February 17th. The shares were sold at an average price of $24.32, for a transaction totalling $2,188,800.00. Learn More on William F. Feehery's trading history.

Who are Certara's active insiders?

Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.

Are insiders buying or selling shares of Certara?

During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 6 times. They sold a total of 92,328 shares worth more than $1,597,961.60. The most recent insider tranaction occured on February, 12th when SVP Richard M Traynor sold 6,000 shares worth more than $108,000.00. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.

Information on this page was last updated on 2/12/2024.

William F. Feehery Insider Trading History at Certara

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/17/2022Sell90,000$24.32$2,188,800.00View SEC Filing Icon  
1/26/2022Sell75,000$25.37$1,902,750.00View SEC Filing Icon  
12/22/2021Sell75,000$28.58$2,143,500.00View SEC Filing Icon  
12/7/2021Sell70,000$27.77$1,943,900.00View SEC Filing Icon  
12/3/2021Sell70,000$26.02$1,821,400.00View SEC Filing Icon  
11/24/2021Sell145,000$28.43$4,122,350.00View SEC Filing Icon  
11/19/2021Sell70,000$30.31$2,121,700.00View SEC Filing Icon  
10/27/2021Sell75,000$39.24$2,943,000.00View SEC Filing Icon  
9/22/2021Sell75,000$36.37$2,727,750.00View SEC Filing Icon  
8/25/2021Sell75,000$31.28$2,346,000.003,138,743View SEC Filing Icon  
7/28/2021Sell75,000$26.16$1,962,000.003,163,051View SEC Filing Icon  
6/23/2021Sell75,000$26.53$1,989,750.003,238,251View SEC Filing Icon  
See Full Table

William F. Feehery Buying and Selling Activity at Certara

This chart shows William F Feehery's buying and selling at Certara by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Certara Company Overview

Certara logo
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $17.88
Low: $17.70
High: $18.48

50 Day Range

MA: $17.47
Low: $16.10
High: $19.45

2 Week Range

Now: $17.88
Low: $11.81
High: $24.96

Volume

632,713 shs

Average Volume

591,967 shs

Market Capitalization

$2.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62